Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) obtained approval from China's National Medical Products Administration for the clinical trials of five drugs, according to a Shanghai bourse filing on Saturday.
The pharmaceutical company's Hong Kong shares slipped by less than 1% during Monday's morning trade.
The drugs, which all target tumors and various cancer cells, to be tested are HRS-6093 tablets, SHR-9839 for injection (sc), SHR-1826 for injection, adebrelimab injection and SHR-8068 injection.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments